ReviewArthritis research & therapy2005
Primary and secondary autoimmune neutropenia.
Review in Arthritis research & therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 172 citations in OpenAlex.
- Phenotype-specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20-year cohort study.British journal of haematology · 2026Article
- Chronic Neutropenia in Children: A Single-Center Experience.Acta medica academica · 2026Article
- Detection and Identification of Anti-Neutrophil Antibodies in Immune Neutropenia: Integrating Serology, Genotyping and Clinical Interpretation.Antibodies (Basel, Switzerland) · 2026Review
- Analysis of infectious complications in paediatric autoimmune neutropenia: a French nationwide retrospective cohort study.Archives of disease in childhood · 2026Article
- Multidisciplinary Treatment for Cecal Cancer and Metachronous Liver Metastases in a Patient with Primary Autoimmune Neutropenia.Surgical case reports · 2025Article
- Effect of the autoimmune-associated genetic variantFrontiers in immunology · 2025Article
- A Case of Autoimmune Neutropenia That Responded to Rituximab.Journal of medical cases · 2024Article
- Natural history of chronic idiopathic neutropenia of the adult.Scientific reports · 2024Article
- Neutropenia in Childhood-A Narrative Review and Practical Diagnostic Approach.Hematology reports · 2024Review
- [Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases].Zeitschrift fur Rheumatologie · 2024Review
- A case of idiopathic multicentric Castleman's disease with secondary autoimmune neutropenia.Respirology case reports · 2024Article
- A Case of Autoimmune Neutropenia in a Patient Undergoing Breast Cancer Surgery.Case reports in surgery · 2024Article
- The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey.Frontiers in neurology · 2023Article
- Autoimmune Neutropenias: Update on Clinical and Biological Features in Children and Adults.HemaSphere · 2023Review
- Felty's syndrome.Frontiers in medicine · 2023Review
- Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case report.Translational andrology and urology · 2022Article
- How to Make the Right Diagnosis in Neutropenia.Clinical hematology international · 2021Review
- Two Cases of Autoimmune Neutropenia Complicated with Other Lineages of Autoimmune Cytopenia, Successfully Treated with Prednisolone.Internal medicine (Tokyo, Japan) · 2021Article
- Possible involvement of regulatory T cell abnormalities and variational usage of TCR repertoire in children with autoimmune neutropenia.Clinical and experimental immunology · 2021Article
- Primary autoimmune neutropenia of infancy and childhood in a cohort of patients from western Romania.Experimental and therapeutic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antineutrophil antibodies are well recognized causes of neutropenia, producing both quantitative and qualitative defects in neutrophils and increased risk for infection. In primary autoimmune neutropenia (AIN) of infancy, a moderate to severe neutropenia is the sole abnormality; it is rarely associated with serious infections and exhibits a self-limited course. Chronic idiopathic neutropenia of adults is characterized by occurrence in late childhood or adulthood, greater prevalence among females than among males, and rare spontaneous remission. Secondary AIN is more commonly seen in adults and underlying causes include collagen disorders, drugs, viruses and lymphoproliferative disorders. In most patients with AIN, antibodies recognize antigens located on the IgG Fc receptor type 3b but other target antigens have been recently identified in secondary AIN. Granulocyte colony-stimulating factor is a proven treatment in patients with AIN of all types and is now preferred to other possible therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.